Biomarkers /
XPO1
Overview
Exportin 1 (XPO1) is a gene that encodes a protein that medicates leucine-rich nuclear export signal-dependent protein transport and inhibits nuclear export of specific molecules. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
XPO1 is altered in 1.19% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and diffuse large B-cell lymphoma, not otherwise specified having the greatest prevalence of alterations [3].
The most common alterations in XPO1 are XPO1 Mutation (0.97%), XPO1 Amplification (0.15%), XPO1 E571K (0.13%), XPO1 R749Q (0.05%), and XPO1 R261Q (0.02%) [3].
Clinical Trials
Significance of XPO1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.